Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease

BMC Neurol. 2015 Feb 5;15:8. doi: 10.1186/s12883-015-0260-1.


Background: Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer's disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia.

Methods: We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias.

Results: We observed similar plasma anti-PC levels in controls, patients with Alzheimer's disease, and other dementias.

Conclusions: Our data suggests that anti-PC is not useful as a biomarker for Alzheimer's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / blood*
  • Antibodies / blood*
  • Biomarkers / blood
  • Case-Control Studies
  • Dementia / blood
  • Female
  • Humans
  • Male
  • Middle Aged
  • Phosphorylcholine / immunology*


  • Antibodies
  • Biomarkers
  • Phosphorylcholine